Arcellx (ACLX) Operating Expenses (2021 - 2025)
Arcellx's quarterly Operating Expenses came in at $65.3 million in Q4 2025, down 4.5% year-on-year from $68.4 million in Q4 2024, and down 2.08% quarter-over-quarter from $66.7 million in Q3 2025.
Arcellx has reported Operating Expenses for 5 years, with the latest figure at $65.3 million in Q4 2025.
- For the quarter ending Q4 2025, Operating Expenses fell 4.5% year-over-year to $65.3 million; the trailing twelve-month figure through Dec 2025 stood at $275.4 million (up 12.16% YoY), and the FY2025 full-year result was $275.4 million, up 12.16% from the prior year.
- Operating Expenses for Q4 2025 stood at $65.3 million, down from $66.7 million in the prior quarter.
- The five-year high for Operating Expenses was $93.9 million in Q3 2022, with the low at $11.3 million in Q1 2021.
- Average Operating Expenses over 5 years is $48.9 million, with a median of $51.7 million recorded in 2023.
- Year-over-year, Operating Expenses surged 448.66% in 2022 and plunged 36.28% in 2023.
- Tracing ACLX's Operating Expenses over 5 years: stood at $20.7 million in 2021, then soared by 93.27% to $40.0 million in 2022, then increased by 20.36% to $48.1 million in 2023, then jumped by 42.1% to $68.4 million in 2024, then slipped by 4.5% to $65.3 million in 2025.
- The last three Operating Expenses figures came in at $65.3 million (Q4 2025), $66.7 million (Q3 2025), and $66.3 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.33 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -138.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.85 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 898.54 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 65.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 65.34 Mn |
| Sep 30, 2025 | 66.73 Mn |
| Jun 30, 2025 | 66.28 Mn |
| Mar 31, 2025 | 77.03 Mn |
| Dec 31, 2024 | 68.42 Mn |
| Sep 30, 2024 | 59.65 Mn |
| Jun 30, 2024 | 62.38 Mn |
| Mar 31, 2024 | 55.07 Mn |
| Dec 31, 2023 | 48.15 Mn |
| Sep 30, 2023 | 59.82 Mn |
| Jun 30, 2023 | 43.86 Mn |
| Mar 31, 2023 | 48.37 Mn |
| Dec 31, 2022 | 40.00 Mn |
| Sep 30, 2022 | 93.88 Mn |
| Jun 30, 2022 | 31.29 Mn |
| Mar 31, 2022 | 26.09 Mn |
| Dec 31, 2021 | 20.70 Mn |
| Sep 30, 2021 | 17.11 Mn |
| Jun 30, 2021 | 15.93 Mn |
| Mar 31, 2021 | 11.28 Mn |